Table 3

Examples of recent PIPs for drugs in T2D approved by the EMA

DrugAnticipated completion date
TaspoglutideMarch 2017
EmpagliflozinFebruary 2019
ExenatideJuly 2019
AlogliptinMay 2020
AlbiglutideApril 2021
OmarigliptinFebruary 2022
DulaglutideJune 2022
LixisenatideOctober 2022
SotagliflozinFebruary 2024
ErtugliflozinMarch 2026
Glucagon receptor antagonistJuly 2027